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ABSTRACT
Objectives: To assess the prevalence and patterns of
cardiac abnormalities as detected by cardiac magnetic
resonance imaging (MRI) in systemic sclerosis (SSc).
Methods: Fifty-two consecutive patients with SSc
underwent cardiac MRI to determine morphological,
functional, perfusion at rest and delayed enhancement
abnormalities.
Results: At least one abnormality on cardiac MRI was
observed in 39/52 patients (75%). Increased myocardial
signal intensity in T2 was observed in 6 patients (12%),
thinning of left ventricle (LV) myocardium in 15 patients
(29%) and pericardial effusion in 10 patients (19%). LV
and right ventricle (RV) ejection fractions were altered in
12 patients (23%) and 11 patients (21%), respectively. LV
diastolic dysfunction was found in 15/43 patients (35%).
LV kinetic abnormalities were found in 16/52 patients
(31%) and myocardial delayed contrast enhancement was
detected in 11/52 patients (21%). No perfusion defects at
rest were found. Patients with limited SSc had similar
MRI abnormalities to patients with diffuse SSc. Seven of
40 patients (17%) without pulmonary arterial hypertension
had RV dilatation.
Conclusions: This study shows that MRI is a reliable and
sensitive technique for diagnosing heart involvement in
SSc and for analysing its mechanisms, including its
inflammatory, microvascular and fibrotic components.
Compared with echocardiography, MRI appears to provide
additional information by visualising myocardial fibrosis
and inflammation. RV dilatation appeared to be non-
specific for pulmonary arterial hypertension but could also
reflect myocardial involvement related to SSc. Further
studies are needed to determine whether cardiac MRI
abnormalities have an impact on the prognosis and
treatment strategy.
Heart involvement in systemic sclerosis (SSc)
affects the prognosis of the disease when it is
clinically evident.
1 Myocardial fibrosis is the
pathological hallmark of this complication and
has been reported in 50–80% of cases in necropsy
studies, whereas it is rarely clinically obvious.
23
The main limitation of the usual methods of
assessing heart involvement (echocardiography,
perfusion scan) is that they are not specific for
myocardial fibrosis.
45Cardiac magnetic resonance
imaging (MRI) is a recent, accurate and sensitive
method of studying heart structure and function
non-invasively and precisely.
67 Previous studies
have shown that MRI is helpful in the diagnosis
of acute inflammatory myocarditis
8 and myocar-
dial fibrosis.
69Three studies have recently assessed
the usefulness of cardiac MRI in SSc, focusing
either on delayed contrast enhancement abnorm-
alities,
6 on ventricular volumes and ejection frac-
tions
10 or on perfusion index.
11 The aims of our
study were to perform a comprehensive analysis of
cardiac MRI in SSc and to compare the cardiac
MRI findings according to the clinical features
including cutaneous extension and the presence of
pulmonary arterial hypertension (PAH).
METHODS
Patients
Fifty-two consecutive unselected patients followed
up at the Reference Centre for Scleroderma in Lille,
France and fulfilling the American College of
Rheumatology criteria for the diagnosis of SSc
12
and/or LeRoy’s classification criteria for SSc
13 were
enrolled in this cross-sectional observational study.
Clinical assessment collected data on age at
onset of the first symptom of SSc except
Raynaud’s phenomenon, age at onset of
Raynaud’s phenomenon and cutaneous extension
graded according to the LeRoy classification.
13
Overt coronary arterial disease was excluded based
on clinical examination and a systematic ECG.
All patients underwent Doppler echocardiogra-
phy (Philips Sonos 5500; Philips Medical Systems,
Andover, Massachusetts, USA) by a senior cardiol-
ogist (PDG) within 1 month before or after MRI.
PAH was suspected in patients with a peak
velocity of tricuspid regurgitation (VTR) .2.5–
3 m/s and unexplained dyspnoea, or with VTR
.3 m/s and warranted confirmatory right heart
catheterisation.
14 Left ventricular (LV) systolic
dysfunction was defined as an LV ejection fraction
of (45%.
Cardiac magnetic resonance imaging
Protocol
None of the patients had any contraindications for
a cardiac MRI, especially renal insufficiency, which
has been involved in nephrogenic systemic fibrosis.
The examination was performed on a 1.5 Tesla
MR scan (Intera, Philips Medical Systems, Best,
The Netherlands). After localisation of the four
planes of the heart (short axis, SA; long axis, LA; 4
chambers, 4CH; aortic root plane, AR), a turbo
spin-echo sequence balanced in T2 black blood in
the SA of the heart was performed. A cine-balanced
turbo fast echo sequence was performed in three
axes (SA, 4CH, AR). After a single injection of
0.1 mmol/kg meglumine gadoterate (Dotarem,
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assessed by an echo-double diffusion imaging sequence in the
SA plane. After a second dose of 0.1 mmol/kg meglumine
gadoterate, the delayed contrast enhancement sequence was
performed in three cardiac axes (SA, LA, 4CH). At the end of the
examination a velocimetric sequence centred on the mitral valve
was performed.
Imaging data analysis
The myocardium was studied in 17 segments according to the
American Heart Association standardised myocardial segmenta-
tion.
15 The morphological study assessed the presence of
increased intramyocardial signal intensity on T2-weighted
images. A thickness of (4 mm was considered as a thinned
myocardium. Right ventricular (RV) hypertrophy was defined
by a thickness of >5 mm. The presence of LV and/or RV
dilatation was defined as an increased indexed LV and/or RV
end-diastolic volume compared with available normal values.
16–18
An impaired LV or RV ejection fraction was defined according
to normal values provided by Maceira et al.
16 18
Delayed contrast enhancement was defined as an area
fulfilling all of the following criteria: a signal intensity value
.2 SD above the normal myocardium,
19 presence in the same
myocardial segment in at least two different planes, and
presence in identical planes on two different acquisitions with
the appropriate inversion time. MRI abnormalities were
independently assessed by two expert radiologists (ALH and
VG) blinded to the clinical findings. In cases of discrepancy, a
consensus was reached by discussion.
Statistical analysis
All data are presented as mean (SD) or as frequencies (n (%)).
Comparisons of means were performed with the non-para-
metric Wilcoxon test, comparisons of frequencies with the x
2 or
Fisher exact tests. Correlations between numerical parameters
were evaluated using Pearson’s correlation. Statistical analyses
were performed with SAS software Version 9.1 (SAS Institute,
Cary, North Carolina, USA).
RESULTS
Clinical characteristics
The clinical characteristics of the patients are shown in table 1.
No patient had overt left heart failure.
Pattern and distribution of cardiac MRI abnormalities
When we excluded mitral flow impairment which was not
interpretable in all patients, cardiac MRI showed at least one
abnormality in 39 of the 52 patients (75%). The main MRI
abnormalities are shown in fig 1.
Morphological study
Increased signal intensity on T2-weighted sequences was found
in 6 patients (12%, fig 2), always in the LV myocardium and
mainly transmural (5 patients). None of these 6 patients had
inflammatory markers. The mean (SD) duration of SSc was not
significantly lower in patients with increased signal intensity
(7.0 (6.3) vs 4.3 (3.8) years, p=0.28). A thinning of the LV
myocardium was observed in 15 patients (29%, fig 3) and
predominated in the following segments: 7 (mid-anterior
segment) (n=11), 8 (mid-anteroseptal segment) (n=9) and 1
(basal anterior segment) (n=6). No correlation with coronary
artery distribution was observed.
LV and RV dilatation were found in 3 patients (6%) with a
mean (SD) LV indexed end-diastolic volume of 109 (4) ml/m
2
and 11 patients (21%) with a mean (SD) RV indexed end-
diastolic volume of 99 (32) ml/m
2, respectively. The RV was
hypertrophied in 2 patients (4%). A moderate pericardial
effusion was observed in 10 patients (19%).
Perfusion analysis
No perfusion defect at rest was detected by visual analysis.
Functional study
Twelve of the 52 patients (23%) had an impaired LV ejection
fraction (mean (SD) 48 (4)%) and 11 (21%) had an impaired RV
ejection fraction (mean (SD) 34 (9)%) without evidence of overt
cardiac failure in any patient. LV kinetic abnormalities were
found in 16 patients (31%), mainly segmental LV hypokinesia
(n=14) and, more rarely, global LV hypokinesia (n=2). The
abnormalities predominated in segment 7 (mid-anterior seg-
ment; n=9), segment 8 (mid-anteroseptal segment; n=9) and
segment 1 (basal anterior segment; n=5). Segmental LV
dyskinesia was observed in 2 patients and RV dyskinesia was
observed in 5 patients (10%).
The transmitral flow was interpretable in 43 of the 52
patients (83%). An impaired LV relaxation pattern was found in
15 of the 43 patients (35%), a normal pattern in 21 patients
(49%), a pseudonormal pattern in 6 patients (14%) and a
restrictive pattern in 1 patient (2%).
Delayed contrast enhancement
Myocardial delayed contrast enhancement was detected in 11 of
the 52 patients (21%). Delayed contrast enhancement was
Table 1 Clinical characteristics of patient population
M/F, n 44/8
Mean (SD) age (years) 56 (11)
Limited/diffuse cutaneous SSc, n 32/20
Anticentromere antibody, n (%) 21 (40)
Anti-SCL 70 antibody, n (%) 18 (34)
Mean (SD) disease duration since first non-
Raynaud’s phenomenon (years)
6.6 (6.1)
Mean (SD) disease duration since Raynaud’s
phenomenon (years)
11.2 (10.4)
Interstitial lung disease on HRCT, n (%) 25 (48)
Precapillary pulmonary arterial hypertension by right
heart catheterisation, n (%)
12 (23)
Palpitations, n 5
Myositis* 0
Hypertension 15
Elevated serum cholesterol levels 15
Current smokers 9
Diabetes mellitus 2
Body mass index .27 kg/m
2 5
Mean (SD) inspiratory vital capacity (%) 93 (15)
Mean (SD) total lung capacity (%) 95 (14)
Mean (SD) TLCO (%) 59 (25)
Current treatment, n Calcium channel blockers
(n=15); angiotensin-converting
enzyme inhibitors (n=15);
bosentan (n=12); sildenafil
(n=1)
Prednisone, n (mean (SD) dose in mg) 19 (11 (6))
Previous treatment by cyclophosphamide, n 6
Data are mean (SD) or absolute number (%).
*Based on clinical data and creatine phosphokinase level.
HRCT, high-resolution CT of the chest; SSc, systemic sclerosis; TLCO, carbon monoxide
transfer factor expressed as percentage of theoretical value.
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(n=3/11). It was mid-wall in the majority of patients
(n=8/11) and, more rarely, subendocardial (n=2/11) or
subepicardial (n=1/11). It predominated in segments 7 (mid-
anterior segment; n=5), 8 (mid-anteroseptal segment; n=7)
and 9 (mid-inferoseptal segment; n=6). There was no
correlation with any coronary artery distribution.
Correlation between cardiac MRI abnormalities
Of the 6 patients with increased signal intensity on T2-
weighted sequences, one also had myocardial delayed contrast
enhancement. Of the 15 patients with thinning of the LV
myocardium, 11 had LV kinetic abnormalities. Of the 11
patients with delayed contrast enhancement, 3 had LV kinetic
abnormalities. In the first patient the cardiac segment affected
by kinetic abnormalities had no concomitant delayed contrast
enhancement. In the second patient the segment affected by
kinetic abnormalities had delayed contrast enhancement. In the
third patient the two segments affected by kinetic abnormalities
had delayed contrast enhancement.
Association between cardiac MRI abnormalities and clinical
presentation of SSc
A comparison of cardiac MRI findings between patients with
limited cutaneous SSc and patients with diffuse cutaneous SSc
is given in table 2, showing no great differences between the
two subtypes except for the frequency of impaired LV ejection
fraction. A comparison of cardiac MRI findings between
patients with and patients without precapillary PAH is shown
in table 3. Mean (SD) pulmonary arterial pressure was 34
(13) mm Hg and mean (SD) cardiac index was 2.93 (0.82) l/
min/m
2. All patients with RV dilatation had undergone a right
heart catheterisation to exclude the presence of either pre-
capillary PAH or postcapillary pulmonary hypertension. Of the
7 patients with RV dilatation but without PAH, 2 also had LV
dilatation. There was a good linear correlation between the
cardiac output measured by MRI and by right heart catheter-
isation (R
2=0.7, p=0.004).
Concerning the duration of SSc before cardiac MRI, we found
that the longer the disease duration from the first symptom of
non-Raynaud’s phenomenon, the greater the number of cardiac
segments presenting kinetic abnormalities (r=0.29, p,0.05)
Figure 1 Frequencies of the main MRI abnormalities. LV, left ventricle; RV, right ventricle.
Figure 2 Anteroseptal and lateral (arrows) transmural nodular
increased signal intensity in T2-weighted sequence on an MRI 1.5 Tesla
scan (Intera, Philips Medical Systems, Best, The Netherlands).
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Raynaud’s phenomenon as the first sign of SSc, we found that
the longer the disease duration, the greater the number of
cardiac segments presenting kinetic abnormalities (r=0.35,
p,0.05). No correlation was found with delayed contrast
enhancement (r=0.19, p=0.15).
Association between cardiac MRI abnormalities and
echocardiography findings
The association between cardiac abnormalities and echocardio-
graphic findings is shown in table 4. The sensitivity of cardiac
MRI to detect cardiac abnormalities was 39/52 patients (75%)
compared with 25/52 patients (48%) for echocardiography. Of
the 3 patients with LV dilatation on MRI, one also had LV
dilatation on echocardiography. All of the 11 patients with RV
dilatation on MRI had RV dilatation on echocardiography. The
mean (SD) LV ejection fraction obtained by echocardiography
was significantly higher than that obtained by MRI (63 (7)% vs
60 (9)%, p,0.05). There was a significant but weak linear
correlation between LV ejection fraction obtained by these two
investigations (r=0.49, p=0.001).
DISCUSSION
The main results of our study are as follows. First, the majority
(75%) of patients with SSc had at least one abnormality on
cardiac MRI which gives a higher sensitivity than echocardio-
graphy (48%). Second, cardiac MRI enabled us to analyse
precisely the different patterns of heart involvement in SSc by
differentiating morphological, functional, perfusion and delayed
contrast enhancement abnormalities. Third, patients with
limited cutaneous SSc had roughly the same MRI abnormalities
as those with diffuse cutaneous SSc, and RV dilatation was not
specific for PAH. The high frequency of heart abnormalities
observed on cardiac MRI is consistent with necropsy studies
which showed that approximately 80% of patients with SSc had
histological lesions of heart involvement.
23 As in previous
studies,
20 this complication was rarely detectable at the bedside.
Taken together, these results suggest that such alterations are
clinically underestimated and that MRI is highly sensitive. Yet
the clinical significance of MRI abnormalities remains to be
established.
Our study enabled us to distinguish the different patterns of
heart involvement in SSc using MRI. Previous studies have
shown that MRI can accurately detect myocardial fibrosis.
62 1In
myocardial fibrosis the gadolinium is trapped in the fibrosis
while it is washed more rapidly in the normal myocardium,
explaining the delayed contrast enhancement. The myocardial
delayed contrast enhancement observed in our study (fig 3) had
almost the same characteristics as those in the study by Tzelepis
et al,
6 with the same predominance of a mid-wall and linear
pattern. Lesions of the small coronary arteries or arterioles were
recorded in approximately 20% of necropsy cases.
2 In chronic
infarction, myocardial remodelling results in regional thinning
of the myocardium. Thinning of the LV observed in our study
could therefore reflect the chronic coronary microvascular
injury related to SSc. Finally, inflammation is likely to play a
role in SSc as well as in heart involvement.
22 23 Increased signals
on T2-weighted images are indicators of soft tissue oedema.
9 In
the absence of any correlation with coronary artery distribution,
increased signal intensity in T2-weighted images is suggestive of
inflammatory myocarditis.
24–26
Our study also showed that MRI LV and/or RV ejection
fractions were altered in about one-fifth of patients according to
the reference values of Maceira et al,
16 18 although the mean
values remained within the normal range and patients had no
Figure 3 Short axis of the right and left ventricle in cine-MRI sequence
showing the thickness of the left ventricle myocardium (end-diastolic
frame).
Figure 4 Mid-wall linear late enhancement (arrows) in anteroseptal location assessed by delayed enhancement sequence 10 min after Gd-DTPA
injection on an MRI 1.5 Tesla scan. (A) Four chambers; (B) short axis; (C) long axis.
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ejection fractions is most likely a direct consequence of
myocardial fibrosis, as previously suggested.
10 27
We did not find any perfusion defect on cardiac MRI in
patients with SSc. This is consistent with the absence of
increased coronary artery arteriosclerosis in SSc.
2 However, we
must acknowledge that our technique may have lacked
sensitivity,
11 precluding the possibility to see perfusion defects
usually observed using thallium perfusion scans.
28
Interestingly, we found no significant differences in cardiac
MRI abnormalities between patients with limited cutaneous
SSc and those with diffuse cutaneous SSc. These results are
consistent with a previous study in which heart symptoms were
not found to be significantly different between the two
Table 2 Comparison of cardiac MRI findings between patients with limited cutaneous SSc and patients with
diffuse cutaneous SSc
Limited cutaneous SSc
(n=32)
Diffuse cutaneous SSc
(n=20) p Value
Patients with at least one cardiac MRI abnormality, n (%) 24 (75) 15 (75) 1.00
Morphological abnormalities
Increased signal intensity in T2-weighted sequence, n
(%)
2 (7) 4 (20) 0.20
Thinned LV myocardium, n (%) 8 (25) 7 (35) 0.44
LV dilatation, n (%) 1 (3) 2 (10) 0.55
RV hypertrophy, n (%) 1 (3) 1 (5) 1.00
RV dilatation, n (%) 5 (16) 6 (30) 0.29
Pericardial effusion, n (%) 7 (22) 3 (15) 0.72
Functional abnormalities
LV kinetic abnormalities, n (%) 10 (31) 6 (30) 0.92
RV kinetic abnormalities, n (%) 3 (9) 2 (10) 1.00
Mean (SD) LV ejection fraction, % 59 (10) 62 (7) 0.20
Impaired LV ejection fraction 11 (34) 1 (5) 0.02
Mean (SD) LV end-diastolic volumes, ml/m
2 68 (14) 69 (17) 1.00
Mean (SD) cardiac output, l/min 4.8 (1.4) 5.6 (1.3) 0.04
Mean (SD) RV ejection fraction, % 52 (12) 50 (10) 0.31
Impaired RV ejection fraction, n (%) 6 (19) 5 (25) 0.73
Mean (SD) RV end-diastolic volumes, ml/m
2 73 (11) 87 (28) 0.03
LV diastolic dysfunction on transmitral flow analysis, n
(%)
11/29 (38) 4/14 (7) 0.41
Delayed contrast enhancement, n (%) 6 (19) 5 (25) 0.73
Data are mean (SD) or absolute number (%).
LV, left ventricle; RV, right ventricle; SSc, systemic sclerosis.
Table 3 Comparison of cardiac MRI findings between patients with and patients without precapillary
pulmonary arterial hypertension (PAH)
Patients with PAH
(n=12)
Patients without PAH
(n=40) p Value
Patients with at least one cardiac MRI abnormality,
n (%)
9 (75) 30 (75) 1.00
Morphological abnormalities
Increased signal intensity in T2 weighted sequence,
n (%)
3 (27) 3 (8) 0.11
Thinned LV myocardium, n (%) 4 (33) 11 (8) 0.72
LV dilatation, n (%) 1 (8) 2 (5) 0.55
RV hypertrophy, n (%) 2 (17) 0 (0) 0.04
RV dilatation, n (%) 4 (33) 7 (17) 0.25
Pericardial effusion, n (%) 5 (42) 5 (13) 0.04
Functional abnormalities
LV kinetic abnormalities, n (%) 3 (25) 13 (32) 0.73
RV kinetic abnormalities, n (%) 2 (17) 3 (8) 0.32
Mean (SD) LV ejection fraction, % 61 (10) 60 (8) 0.69
Impaired LV ejection fraction, n (%) 3 (25) 9 (23) 1.00
Mean (SD) LV end-diastolic volumes, ml/m
2 66 (18) 69 (14) 0.39
Mean (SD) cardiac output, l/min 5.6 (1.7) 5.0 (1.2) 0.21
Mean (SD) RV ejection fraction, % 54 (13) 50 (11) 0.20
Impaired RV ejection fraction, n (%) 2 (17) 9 (23) 1.00
Mean (SD) RV end-diastolic volumes, ml/m
2 75 (9) 79 (23) 0.67
LV diastolic dysfunction on transmitral flow analysis,
n (%)
5 (50) 10 (30) 0.49
Delayed contrast enhancement, n (%) 1 (8) 10 (26) 0.42
LV, left ventricle; PAH, precapillary pulmonary arterial hypertension on right heart catheterisation; RV, right ventricle.
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1 We have recently shown that echocardiographic
abnormalities did not differ between diffuse and limited
cutaneous SSc.
4 We found that LV ejection fraction was more
often altered in patients with limited cutaneous SSc, although
no patients had overt cardiac failure and mean values remained
in the normal range.
Up to 17% of the patients in our study without PAH had RV
dilatation. It is noteworthy that all these patients underwent
right heart catheterisation to rule out PAH. This is further
evidence for the specific involvement of the RV in SSc, most
probably related to myocardial fibrosis. PAH was rather mild in
our study, which probably explains why some patients with
PAH had no RV dilatation.
With regard to the comparison of data provided by
echocardiography and cardiac MRI, we found that cardiac
MRI provides additional information. Some analyses were not
possible by echocardiography, most notably delayed contrast
enhancement, increased signal intensity and thinned myocar-
dium. However, echocardiography is more useful in valvular
heart diseases, especially in PAH screening with tricuspid
gradient evaluation. The correlation between LV ejection
fraction obtained by MRI and by echocardiography was not
good, which has been reported previously.
29
Our study shows that patients with a longer disease duration
had more kinetic abnormalities and delayed contrast enhance-
ment, which is consistent with previous studies.
63 0 These
results suggest a progression of myocardial fibrosis over time
and therefore a natural history of heart involvement in SSc. This
natural history could be longitudinally studied by repeated
cardiac MRI.
We acknowledge that our study has some limitations. There
was no histological confirmation of our imaging data since this
procedure was judged to be too invasive to be incorporated into
the study. We did not include a control group of healthy
subjects, thus precluding any firm conclusions regarding the
higher frequency of abnormalities. Results from a 3 Tesla MRI
scan may have provided more detailed information on the
extent of fibrosis and its morphology. We did not systematically
measure B-type natriuretic peptide and troponin levels.
Our study shows that MRI is an accurate and reliable
technique for diagnosing heart involvement in SSc and for
analysing precisely its mechanisms including inflammatory,
microvascular and fibrotic components. As it is non-invasive,
quantitative and highly sensitive, MRI appears to be the
method of choice to determine the natural history of untreated
patients or to monitor accurately the effects of treatment.
Moreover, it could provide powerful prognostic factors in both
groups. Compared with echocardiography, MRI appears to
provide additional information by visualising myocardial
fibrosis and inflammation. Finally, we have shown that RV
dilatation is not specific for PAH and could correspond to a
specific heart involvement in SSc. Further studies are required to
determine whether cardiac MRI abnormalities have a significant
clinical impact on the prognosis and treatment strategy.
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